CY1111272T1 - Αναλυση σακχαρικων εμβολιων χωρις παρεμβολες - Google Patents
Αναλυση σακχαρικων εμβολιων χωρις παρεμβολεςInfo
- Publication number
- CY1111272T1 CY1111272T1 CY20111100075T CY111100075T CY1111272T1 CY 1111272 T1 CY1111272 T1 CY 1111272T1 CY 20111100075 T CY20111100075 T CY 20111100075T CY 111100075 T CY111100075 T CY 111100075T CY 1111272 T1 CY1111272 T1 CY 1111272T1
- Authority
- CY
- Cyprus
- Prior art keywords
- saccharides
- analysis
- glucose
- serological
- serological groups
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 6
- 230000000405 serological effect Effects 0.000 abstract 5
- 150000002772 monosaccharides Chemical group 0.000 abstract 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 3
- 239000008103 glucose Substances 0.000 abstract 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 2
- 229930182830 galactose Natural products 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 108010060123 Conjugate Vaccines Proteins 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229940031670 conjugate vaccine Drugs 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 238000003908 quality control method Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Seasonings (AREA)
Abstract
Η εφεύρεση βασίζεται σε μεθόδους που επιτρέπουν την ανάλυση μικτών σακχαριτών μηνιγγιτιδοκόκκου από πολλαπλές ορολογικές ομάδες ακόμη και αν μοιράζονται μονάδες μονοσακχαριτών. Με ένα συνδυασμό σακχαριτών από τις ορολογικές ομάδες C, W135 και Υ, η εφεύρεση αναλύει περιεκτικότητα σε σιαλικό οξύ, γλυκόζη και γαλακτόζη. Τα αποτελέσματα της γλυκόζης και γαλακτόζης χρησιμοποιούνται για την άμεση ποσοτικοποίηση σακχαριτών από τις ορολογικές ομάδες Υ και W135, αντίστοιχα, και η συνδυασμένη περιεκτικότητα γλυκόζης και γαλακτόζης αφαιρείται από την περιεκτικότητα σιαλικού οξέος για να ποσοτικοποιηθούν οι σακχαρίτες από την ορολογική ομάδα C. Οι τρεις ορολογικές ομάδες μπορούν με αυτόν τον τρόπο να διαχωριστούν αν και οι περιεκτικότητες τους σε μονοσακχαρίτες επικαλύπτονται. Οι τρεις διαφορετικές αναλύσεις μονοσακχαριτών μπορούν να γίνουν στο ίδιο υλικό, χωρίς παρεμβολή μεταξύ των μονοσακχαριτών και χωρίς παρεμβολή από οποιοδήποτε άλλο σακχαρικό υλικό στην σύνθεση (π.χ. σταθεροποιητές λυοφίλησης). Η μέθοδος μπορεί να χρησιμοποιηθεί για την ανάλυση ολικού και ελεύθερου σακχαρίτου σε συζευγμένα εμβόλια και απλοποιεί τον ποιοτικό έλεγχο εμβολίων που περιέχουν καψικούς σακχαρίτες από πολλαπλές ορολογικές ομάδες.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0406013.3A GB0406013D0 (en) | 2004-03-17 | 2004-03-17 | Analysis of saccharide vaccines without interference |
| EP05718447A EP1725872B8 (en) | 2004-03-17 | 2005-03-17 | Analysis of saccharide vaccines without interference |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111272T1 true CY1111272T1 (el) | 2015-08-05 |
Family
ID=32117883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100075T CY1111272T1 (el) | 2004-03-17 | 2011-01-24 | Αναλυση σακχαρικων εμβολιων χωρις παρεμβολες |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8137680B2 (el) |
| EP (4) | EP1725871B8 (el) |
| JP (2) | JP4692852B2 (el) |
| CN (1) | CN1981195B (el) |
| AT (2) | ATE500510T1 (el) |
| AU (2) | AU2005224459B2 (el) |
| BR (1) | BRPI0508890A (el) |
| CA (1) | CA2560224C (el) |
| CY (1) | CY1111272T1 (el) |
| DE (2) | DE602005024523D1 (el) |
| ES (1) | ES2353701T3 (el) |
| GB (1) | GB0406013D0 (el) |
| HK (1) | HK1098192A1 (el) |
| NZ (2) | NZ570193A (el) |
| PL (1) | PL1725872T3 (el) |
| PT (1) | PT1725872E (el) |
| RU (1) | RU2371725C2 (el) |
| SI (1) | SI1725872T1 (el) |
| WO (2) | WO2005090986A2 (el) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0411387D0 (en) * | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
| GB0524782D0 (en) * | 2005-12-05 | 2006-01-11 | Chiron Srl | Analysis of samples |
| GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
| GB0612854D0 (en) | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| US8797995B2 (en) * | 2007-01-18 | 2014-08-05 | Cisco Technology, Inc. | Device-assisted layer 3 handoff for mobile services |
| GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| US8207298B2 (en) * | 2008-05-01 | 2012-06-26 | Archemix Corp. | Methods of separating biopolymer conjugated molecules from unconjugated molecules |
| TW201009337A (en) * | 2008-05-30 | 2010-03-01 | Intervet Int Bv | Analytical method to monitor vaccine potency and stability |
| US20100098021A1 (en) * | 2008-10-16 | 2010-04-22 | Cisco Technology, Inc. | Policy-driven layer 3 handoff for mobile services |
| CA2859055A1 (en) * | 2010-03-10 | 2011-09-15 | Inovobiologic, Inc. | Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders |
| PT3246044T (pt) | 2010-08-23 | 2021-02-15 | Wyeth Llc | Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis |
| NZ607224A (en) | 2010-09-10 | 2014-11-28 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| NZ628449A (en) | 2012-03-09 | 2016-04-29 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| JP2015518845A (ja) | 2012-05-22 | 2015-07-06 | ノバルティス アーゲー | 髄膜炎菌血清群ｘコンジュゲート |
| CN102735809B (zh) * | 2012-06-29 | 2015-04-29 | 成都欧林生物科技股份有限公司 | 测定Hib结合疫苗中高分子结合物含量的方法 |
| US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
| EP4098276A1 (en) | 2013-09-08 | 2022-12-07 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| CZ2014451A3 (cs) | 2014-06-30 | 2016-01-13 | Contipro Pharma A.S. | Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití |
| KR20170103009A (ko) | 2015-02-19 | 2017-09-12 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
| CZ309295B6 (cs) | 2015-03-09 | 2022-08-10 | Contipro A.S. | Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití |
| CZ2015398A3 (cs) | 2015-06-15 | 2017-02-08 | Contipro A.S. | Způsob síťování polysacharidů s využitím fotolabilních chránicích skupin |
| CZ306662B6 (cs) | 2015-06-26 | 2017-04-26 | Contipro A.S. | Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití |
| CZ308106B6 (cs) | 2016-06-27 | 2020-01-08 | Contipro A.S. | Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití |
| CN118021947A (zh) | 2017-01-31 | 2024-05-14 | 辉瑞大药厂 | 脑膜炎奈瑟菌组合物及其使用方法 |
| KR20210044805A (ko) * | 2018-08-06 | 2021-04-23 | 닐슨 바이오사이언스, 아이엔씨. | 사마귀의 치료 |
| CA3152573A1 (en) | 2019-10-01 | 2021-04-08 | Biological E Limited | Methods for quantification of carbohydrates |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB323103A (en) | 1928-12-07 | 1929-12-24 | Fred Cunningham Firth | Improvements relating to shaper mechanism for winding yarn on weft bobbins in spinning mules |
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
| US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| RU2023448C1 (ru) | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
| NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| JPH04506662A (ja) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| DE69130136T2 (de) | 1990-06-21 | 1999-03-11 | Oxford Glycosciences Uk Ltd | Automatisiertes Verfahren zur Spaltung von Biomolekülen |
| ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
| AU4841693A (en) | 1992-08-31 | 1994-03-29 | North American Vaccine, Inc. | Vaccines against group c neisseria meningitidis |
| HUP9802199A3 (en) | 1995-06-07 | 1999-07-28 | Smithkline Beecham Biolog | Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| AU754256C (en) * | 1997-12-23 | 2004-05-20 | Pfizer Ireland Pharmaceuticals | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| EP1071465A1 (en) | 1998-03-18 | 2001-01-31 | Ronai, Peter | Amorphous glasses for stabilising sensitive products |
| AU771330B2 (en) | 1998-08-19 | 2004-03-18 | Baxter Healthcare Sa | Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide |
| MY125387A (en) | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
| FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
| AU781027B2 (en) | 1999-04-09 | 2005-04-28 | Department Of Health & Human Services | Recombinant toxin a protein carrier for polysaccharide conjugate vaccines |
| ES2507100T3 (es) | 2000-01-17 | 2014-10-14 | Novartis Vaccines And Diagnostics S.R.L. | Vacuna OMV suplementada contra meningococo |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| AU2001280883A1 (en) | 2000-07-27 | 2002-02-13 | The Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| MXPA03006561A (es) | 2001-01-23 | 2004-10-15 | Aventis Pasteur | Vacuna del conjugado proteina-polisacarido meningococico, multivalente. |
| US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| CN1410532A (zh) * | 2002-03-21 | 2003-04-16 | 上海凡华生物技术有限公司 | 一种人/山羊肝嵌合模型的建立及其鉴定方法 |
| PT1777236T (pt) | 2002-03-26 | 2017-02-13 | Glaxosmithkline Biologicals Sa | Sacáridos modificados possuindo estabilidade melhorada em água para utilização como um medicamento |
| JP4061960B2 (ja) * | 2002-04-26 | 2008-03-19 | 株式会社日立製作所 | コンピュータシステム |
| CN1428434A (zh) * | 2002-11-14 | 2003-07-09 | 中国科学院水生生物研究所 | 一种检测微囊藻产毒的方法 |
| EP2386313A1 (en) * | 2003-05-07 | 2011-11-16 | Sanofi Pasteur, Inc. | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
| JP2007516219A (ja) * | 2003-05-07 | 2007-06-21 | アヴェンティス パストゥール インコーポレイテッド | 髄膜炎菌ワクチン接種に対する免疫原性の増強の方法 |
| CN102023212B (zh) * | 2010-09-28 | 2014-04-02 | 汕头大学医学院 | 一种流感病毒神经氨酸酶抗体的快速检测方法 |
-
2004
- 2004-03-17 GB GBGB0406013.3A patent/GB0406013D0/en not_active Ceased
-
2005
- 2005-03-17 SI SI200531221T patent/SI1725872T1/sl unknown
- 2005-03-17 BR BRPI0508890-9A patent/BRPI0508890A/pt not_active IP Right Cessation
- 2005-03-17 JP JP2007503446A patent/JP4692852B2/ja not_active Expired - Fee Related
- 2005-03-17 RU RU2006136270/15A patent/RU2371725C2/ru not_active IP Right Cessation
- 2005-03-17 EP EP05718410A patent/EP1725871B8/en not_active Revoked
- 2005-03-17 CN CN200580015039XA patent/CN1981195B/zh not_active Expired - Fee Related
- 2005-03-17 CA CA2560224A patent/CA2560224C/en not_active Expired - Fee Related
- 2005-03-17 AT AT05718410T patent/ATE500510T1/de active
- 2005-03-17 EP EP15192029.5A patent/EP3035056A1/en not_active Withdrawn
- 2005-03-17 PL PL05718447T patent/PL1725872T3/pl unknown
- 2005-03-17 EP EP10179759A patent/EP2290366A1/en not_active Withdrawn
- 2005-03-17 ES ES05718447T patent/ES2353701T3/es active Active
- 2005-03-17 WO PCT/IB2005/000987 patent/WO2005090986A2/en active Application Filing
- 2005-03-17 NZ NZ570193A patent/NZ570193A/en not_active IP Right Cessation
- 2005-03-17 DE DE602005024523T patent/DE602005024523D1/de active Active
- 2005-03-17 US US10/593,005 patent/US8137680B2/en not_active Expired - Fee Related
- 2005-03-17 NZ NZ549907A patent/NZ549907A/en not_active IP Right Cessation
- 2005-03-17 WO PCT/IB2005/000946 patent/WO2005090985A1/en active Application Filing
- 2005-03-17 AT AT05718447T patent/ATE487137T1/de active
- 2005-03-17 US US10/593,006 patent/US20080305126A1/en not_active Abandoned
- 2005-03-17 EP EP05718447A patent/EP1725872B8/en not_active Not-in-force
- 2005-03-17 DE DE602005026635T patent/DE602005026635D1/de active Active
- 2005-03-17 PT PT05718447T patent/PT1725872E/pt unknown
- 2005-03-17 AU AU2005224459A patent/AU2005224459B2/en not_active Ceased
-
2007
- 2007-05-28 HK HK07105566.6A patent/HK1098192A1/xx not_active IP Right Cessation
-
2010
- 2010-08-18 JP JP2010183515A patent/JP2011013226A/ja not_active Withdrawn
-
2011
- 2011-01-24 CY CY20111100075T patent/CY1111272T1/el unknown
- 2011-03-03 AU AU2011200950A patent/AU2011200950A1/en not_active Abandoned
-
2012
- 2012-03-12 US US13/418,211 patent/US20120171241A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111272T1 (el) | Αναλυση σακχαρικων εμβολιων χωρις παρεμβολες | |
| Cohen et al. | Modulation of glycan recognition by clustered saccharide patches | |
| Han et al. | Interaction between periodontitis and liver diseases | |
| Park et al. | Characterization of Fusobacterium nucleatum ATCC 23726 adhesins involved in strain-specific attachment to Porphyromonas gingivalis | |
| BRPI0612656A8 (pt) | composição imunogênica, vacina, kit de vacina para a administração concomitante ou sequencial, processo para a produção da vacina, método de imunização de um hospedeiro humano contra doença causada por infecção de neisseria meningitidis, e, uso da composição imunogênica | |
| Zhu et al. | Engineering and dissecting the glycosylation pathway of a streptococcal serine-rich repeat adhesin | |
| Salemi | The intra-host evolutionary and population dynamics of human immunodeficiency virus type 1: a phylogenetic perspective | |
| Li et al. | Synthetic O-acetylated sialosides facilitate functional receptor identification for human respiratory viruses | |
| Heikema et al. | Siglec-7 specifically recognizes Campylobacter jejuni strains associated with oculomotor weakness in Guillain–Barré syndrome and Miller Fisher syndrome | |
| Mubaiwa et al. | The sweet side of the pathogenic Neisseria: the role of glycan interactions in colonisation and disease | |
| Southern et al. | Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine | |
| Azzari et al. | Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice | |
| Lukiw | The microbiome, microbial-generated proinflammatory neurotoxins, and Alzheimer's disease | |
| Gamougam et al. | Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013 | |
| Ozaras et al. | Coronavirus disease 2019 re-infection: first report from Turkey | |
| Mijovic et al. | To LP or not to LP? Identifying the Etiology of Pediatric Meningitis | |
| Schweizer | When it comes to drug discovery not all Gram‐negative bacterial biodefence pathogens are created equal: Burkholderia pseudomallei is different | |
| Calzas et al. | Evaluation of the immunomodulatory properties of Streptococcus suis and Group B Streptococcus capsular polysaccharides on the humoral response | |
| Takahashi et al. | The high mannose-type glycan binding lectin actinohivin: dimerization greatly improves anti-HIV activity | |
| Rinaldi et al. | Ganglioside antibodies and neuropathies | |
| Matsui et al. | Effects of succinylated concanavalin A on infectivity and syncytial formation of human immunodeficiency virus | |
| Heo | Meningococcal disease in Korea: An epidemiologic study of the underestimated infectious disease | |
| Micoli et al. | Meningococcal X polysaccharide quantification by high-performance anion-exchange chromatography using synthetic N-acetylglucosamine-4-phosphate as standard | |
| Nakamura et al. | Binding properties of Clostridium botulinum type C progenitor toxin to mucins | |
| Vandermeulen et al. | A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study |